AbbVie v EMA: Humira study reports provide 'roadmap' for competitors
This article was originally published in SRA
Executive Summary
The EU judge who granted interim injunctions preventing the European Medicines Agency from releasing data on AbbVie’s Humira and InterMune’s Esbriet says there are “complex and delicate” questions to be discussed regarding the balance between commercial interests and the public interest. Moreover, he suggests that even when these interests have been properly weighed, it is “not obvious… that the balance will be clearly in favour of the public interest defended by the EMA”1,2.
You may also be interested in...
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.
EU Warns Of Life-Threatening Interactions Between Paxlovid & Some Immunosuppressants
The EU’s pharmacovigilance committee says that a review of the available evidence showed that in several cases, blood levels of immunosuppressants increased rapidly to toxic levels in patients who were taking the Pfizer drug.